Senti Biosciences Holdings (SNTI) Earnings Date & Reports

Key Takeaways

• Senti Biosciences is expected to report third-quarter 2026 results in mid-November, with consensus estimates pointing to a net loss of roughly $0.21 per share.
• Revenue is forecast to remain minimal — near zero — reflecting the company's status as a clinical-stage biotechnology firm with no approved commercial product.
• Investors will focus heavily on the company's cash position and its "going concern" warning, which management has flagged given limited operating capital.
• The company's lead candidate, SENTI-202, a gene-circuit CAR-NK cell therapy for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), remains the key clinical driver.
• A strategic transformation — including a plan to divest clinical assets in exchange for contingent value rights (CVRs, which entitle holders to future payments if specific milestones are met) — will be a major topic of discussion.
• For additional details on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, visit Tickeron's dedicated SNTI pages.
• You can also explore Trending AI Robots to discover AI-driven trading strategies built around real-time market signals.

Earnings Context and Why It Matters

Senti Biosciences' upcoming report carries outsize importance because it arrives at a pivotal moment for a company navigating both clinical progress and financial pressure. The firm is advancing SENTI-202 toward a pivotal phase after receiving supportive feedback from the U.S. Food and Drug Administration (FDA), yet it has simultaneously warned of "substantial doubt" about its ability to continue as a going concern without additional funding. With cash having declined from $16.4 million at the end of 2025 to roughly $8.9 million by March 2026, and then further during the second quarter, this report will be read primarily as a checkpoint on liquidity and on the progress of its strategic restructuring, rather than as a conventional revenue story.

Earnings Expectations

For the third quarter of 2026, consensus analyst estimates project a net loss of approximately $0.21 per share, though individual estimates in circulation range from about $0.21 to $0.38 per share of losses. Revenue expectations are essentially immaterial, with most forecasts near zero, consistent with a pre-revenue clinical-stage company whose collaboration income has been minimal. For context, the company reported a loss of $0.41 per share in the second quarter of 2026, missing the consensus estimate of roughly $0.33, and a loss of $0.14 per share in the first quarter, which beat expectations. The stock has historically been volatile around earnings, with post-report moves reflecting sentiment on cash runway and clinical updates as much as headline numbers.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening, making it a practical resource for narrowing a watchlist ahead of events like earnings. Explore the AI Screener to streamline your research workflow.

Market Reaction and Investor Sentiment

Sentiment heading into this report is cautious. Senti Biosciences shares have fallen sharply over the past year, reflecting the combined weight of dilution, ongoing losses, and the company's financing uncertainty. The second-quarter results and the accompanying disclosure of a strategic pivot — including a definitive merger agreement to divest clinical assets in exchange for contingent value rights — added complexity to the equity story, and investors will be watching for clarity on that transaction's status. Key risk factors include the pace of cash consumption, the terms and timing of any additional financing, and whether the company can sustain operations while its restructuring proceeds. Given the stock's elevated volatility, the report could trigger a notable move in either direction.

Forward Outlook and Key Factors to Monitor

Beyond the headline loss per share, investors should track several forward-looking items. First, watch the company's disclosed cash balance and any updated runway guidance, as management previously indicated that current capital may only fund operations for a limited number of quarters without new financing.

Second, monitor developments tied to the proposed divestiture of clinical assets and the associated contingent value rights. The structure, timing, and milestone conditions of that transaction will materially shape how shareholders evaluate the company's remaining value.

Third, follow any clinical updates on SENTI-202. Positive FDA engagement supporting a pivotal trial in relapsed or refractory AML remains the most important long-term catalyst for the underlying technology, even as the corporate structure evolves.

Finally, pay attention to operating-expense trends. Recent quarters showed meaningful reductions in research and development (R&D) and general and administrative (G&A) spending, and continued discipline will be essential to extending the runway. As always, these factors should be weighed alongside the inherent risks of clinical-stage biotechnology investing.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations